Advanced

More efficient mobilisation of peripheral blood stem cells with HiDAC plus AMSA plus G-CSF than with mini-ICE plus G-CSF in patients with AML

Hoglund, M; Brune, M; Sallerfors, Bengt LU ; Ahlgren, T; Billström, R; Hedenus, M; Markevarn, B; Nilsson, B; Simonsson, B and Stockelberg, D, et al. (2003) In Bone Marrow Transplantation 32(12). p.1119-1124
Abstract
We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE + filgrastim (second consolidation) and HiDAC + AMSA + filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m(2) + cytarabine 800 mg/m(2) + etoposide 150 mg/m(2) days 1-3) followed by filgrastim 300-480 mug once daily s.c. from day 11 after start of chemotherapy. Only four patients reached >5 CD34+ cells/mul blood (B-CD34+) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. Group... (More)
We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE + filgrastim (second consolidation) and HiDAC + AMSA + filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m(2) + cytarabine 800 mg/m(2) + etoposide 150 mg/m(2) days 1-3) followed by filgrastim 300-480 mug once daily s.c. from day 11 after start of chemotherapy. Only four patients reached >5 CD34+ cells/mul blood (B-CD34+) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. Group B: 20 patients, aged 50 (29-67) years, received HiDAC + AMSA (cytarabine 3 g/m(2) b.i.d. days 1, 3, 5 + amsacrine 150 mg/m(2) q.d. days 2, 4) followed by filgrastim at a similar dose starting on day 7. A total of 18 patients reached B-CD34+ >5/mul and underwent PBSC harvesting, starting on day 23 (14-29) and yielding 4.0 (0.9-21) x 10(6) CD34+ cells/kg. Of 20 patients, 17 (85%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. We conclude that wHiDAC + AMSA + G-CSF - in contrast to mini-ICE + G-CSF - is an efficient regimen for mobilising PBSC in patients with AML CR1. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
haematopoietic stem cell mobilisation, G-CSF, AML, chemotherapy
in
Bone Marrow Transplantation
volume
32
issue
12
pages
1119 - 1124
publisher
Nature Publishing Group
external identifiers
  • wos:000186892300002
  • scopus:0347917174
ISSN
1476-5365
DOI
10.1038/sj.bmt.1704294
language
English
LU publication?
no
id
40ada9eb-6fc0-4566-9db1-e2398954493c (old id 293942)
date added to LUP
2007-09-13 10:39:34
date last changed
2018-05-29 09:22:32
@article{40ada9eb-6fc0-4566-9db1-e2398954493c,
  abstract     = {We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE + filgrastim (second consolidation) and HiDAC + AMSA + filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m(2) + cytarabine 800 mg/m(2) + etoposide 150 mg/m(2) days 1-3) followed by filgrastim 300-480 mug once daily s.c. from day 11 after start of chemotherapy. Only four patients reached >5 CD34+ cells/mul blood (B-CD34+) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. Group B: 20 patients, aged 50 (29-67) years, received HiDAC + AMSA (cytarabine 3 g/m(2) b.i.d. days 1, 3, 5 + amsacrine 150 mg/m(2) q.d. days 2, 4) followed by filgrastim at a similar dose starting on day 7. A total of 18 patients reached B-CD34+ >5/mul and underwent PBSC harvesting, starting on day 23 (14-29) and yielding 4.0 (0.9-21) x 10(6) CD34+ cells/kg. Of 20 patients, 17 (85%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. We conclude that wHiDAC + AMSA + G-CSF - in contrast to mini-ICE + G-CSF - is an efficient regimen for mobilising PBSC in patients with AML CR1.},
  author       = {Hoglund, M and Brune, M and Sallerfors, Bengt and Ahlgren, T and Billström, R and Hedenus, M and Markevarn, B and Nilsson, B and Simonsson, B and Stockelberg, D and Wahlin, A},
  issn         = {1476-5365},
  keyword      = {haematopoietic stem cell mobilisation,G-CSF,AML,chemotherapy},
  language     = {eng},
  number       = {12},
  pages        = {1119--1124},
  publisher    = {Nature Publishing Group},
  series       = {Bone Marrow Transplantation},
  title        = {More efficient mobilisation of peripheral blood stem cells with HiDAC plus AMSA plus G-CSF than with mini-ICE plus G-CSF in patients with AML},
  url          = {http://dx.doi.org/10.1038/sj.bmt.1704294},
  volume       = {32},
  year         = {2003},
}